Orient Europharma. 

TWD42.75
0
-TWD0.65-1.5% 05:30 今天

統計

當日最高
43.5
當日最低
42.75
52週高點
49.6
52週低點
42.6
成交量
21,441
平均成交量
27,141
市值
3.71B
本益比
-
股息殖利率
9.22%
股息
3.94

即將到來

股息

9.22%股息殖利率
2026年8月
TWD4.00
2025年8月
TWD1.00
2024年8月
TWD1.00
2022年8月
TWD0.85
2021年9月
TWD1.50
10年成長
8.31%
5年成長
21.67%
3年成長
不適用
1年成長
300%

財務

-12.35%利潤率
未盈利
2020
2021
2022
2023
2024
2025
4.6B營收
-567.39M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.
顯示更多
執行長
Mon-Lin Tsai
員工
339
國家
台灣
ISIN
TW0004120001

上市

0 則留言

分享你的想法

常見問題

Orient Europharma. 今天的股價是多少?▼
4120.TWO 目前價格為 TWD42.75 TWD,過去 24 小時下跌了 -1.5%。在圖表上更密切關注 Orient Europharma. 股票的表現。
Orient Europharma. 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Taiwan OTC Exchange 交易所,Orient Europharma. 的股票以代號 4120.TWO 進行交易。
Orient Europharma. 的股價在上漲嗎?▼
4120.TWO 股票較上週下跌 -3.39%,本月下跌 -7.27%,過去一年 Orient Europharma. 下跌 -8.06%。
Orient Europharma. 的市值是多少?▼
今天 Orient Europharma. 的市值為 3.71B
Orient Europharma. 去年的營收是多少?▼
Orient Europharma. 去年的營收為 4.6BTWD。
Orient Europharma. 去年的淨利是多少?▼
4120.TWO 去年的淨收益為 -567.39MTWD。
Orient Europharma. 會發放股息嗎?▼
是的,4120.TWO 的股息每 年度 發放一次。每股最新股息為 4 。截至今日,股息殖利率(FWD)% 為 9.22%。
Orient Europharma. 有多少名員工?▼
截至 2026年11月3日,公司共有 339 名員工。
Orient Europharma. 位於哪個產業?▼
Orient Europharma.從事於Health & Wellness產業。
Orient Europharma. 何時完成拆股?▼
Orient Europharma. 上次拆股發生於 2010年7月28日,比例為 1.16:1。
Orient Europharma. 的總部在哪裡?▼
Orient Europharma. 的總部位於 台灣 的 Taipei。